Intra-Cellular Therapies Inc (NASDAQ:ITCI) has been downgraded to Neutral in a statement by SunTrust Banks Inc. earlier today.
- Updated: October 1, 2016
Boasting a price of $42.35, Intra-Cellular Therapies Inc (NASDAQ:ITCI) traded -1.17% lower on the day. With the last stock price close up -58.98% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Intra-Cellular Therapies Inc has recorded a 50-day average of $40.24 and a two hundred day average of $37.16. Volume of trade was up over the average, with 5,567,863 shares of ITCI changing hands over the typical 764,584
SunTrust Banks Inc. has downgraded Intra-Cellular Therapies Inc (NASDAQ:ITCI) to Neutral in a statement released on 9/29/2016.
On Thursday June 02, 2016, Piper Jaffray released a statement for Intra-Cellular Therapies Inc (NASDAQ:ITCI) bumped up the target price from $0.00 to $57.00 that suggested an upside of 0.42%.
With a total market value of $0, Intra-Cellular Therapies Inc has with a one year low of $14.44 and a one year high of $59.96 .
A total of 8 equity analysts have released a ratings update on ITCI. Three equity analysts rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $74.25.
Brief Synopsis About Intra-Cellular Therapies Inc (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company's pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.